drugset / Trial / NCT06823427
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
RandomizedFactorialOpen-labelTreatment
Summary
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.
Timeline
- Start
- 2025-01-17
- Primary completion
- 2026-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | — | — |
| Background | 9MW2821 | Monoclonal antibody | — | — |